Philogen IPO a No-Go After Bayer Nixes Antibody Deal

LONDON – Philogen SpA pulled its initial public offering on the Milan Stock Exchange after partner Bayer Schering Pharma AG peremptorily terminated a licensing and collaboration deal between the two for the development of vascular-targeting antibodies in the treatment of cancer. (BioWorld International)